New pharmacological interventions have targeted bile acid metabolism as a therapeutic approach for MASLD [13] Fibroblast growth factor 19 (FGF19) is a key regulator of bile acid and glucose metabolism in the liver [13] also involved in white adipose tissue browning, which subsequently increasing energy expenditure and protects against obesity [14, 15]. The gene discussed is FGF19; the disease is obesity due to melanocortin 4 receptor deficiency.